MA28989B1 - MOLECULES Fc MODIFIEES - Google Patents

MOLECULES Fc MODIFIEES

Info

Publication number
MA28989B1
MA28989B1 MA29800A MA29800A MA28989B1 MA 28989 B1 MA28989 B1 MA 28989B1 MA 29800 A MA29800 A MA 29800A MA 29800 A MA29800 A MA 29800A MA 28989 B1 MA28989 B1 MA 28989B1
Authority
MA
Morocco
Prior art keywords
molecules
modified
Prior art date
Application number
MA29800A
Other languages
English (en)
Inventor
Colin Gegg
Fei Xiong
Karen C Sitney
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA28989B1 publication Critical patent/MA28989B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA29800A 2004-09-24 2007-04-04 MOLECULES Fc MODIFIEES MA28989B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61268004P 2004-09-24 2004-09-24

Publications (1)

Publication Number Publication Date
MA28989B1 true MA28989B1 (fr) 2007-11-01

Family

ID=35911109

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29800A MA28989B1 (fr) 2004-09-24 2007-04-04 MOLECULES Fc MODIFIEES

Country Status (17)

Country Link
US (7) US7442778B2 (fr)
EP (1) EP1797127B1 (fr)
JP (1) JP5017116B2 (fr)
KR (1) KR100920282B1 (fr)
CN (1) CN101103045B (fr)
AU (1) AU2005289685B2 (fr)
BR (1) BRPI0516011A (fr)
CA (1) CA2580796C (fr)
DK (1) DK1797127T3 (fr)
EA (1) EA011879B1 (fr)
ES (1) ES2629397T3 (fr)
IL (1) IL182139A (fr)
MA (1) MA28989B1 (fr)
MX (1) MX2007003320A (fr)
SI (1) SI1797127T1 (fr)
WO (1) WO2006036834A2 (fr)
ZA (1) ZA200702222B (fr)

Families Citing this family (199)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360496A (en) * 1991-08-26 1994-11-01 Aluminum Company Of America Nickel base alloy forged parts
CN1810832B (zh) 1998-10-23 2012-12-12 麒麟-安姆根有限公司 与MPl受体结合并具有血小板生成活性的模拟二聚体血小板生成素肽
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
HUP0600342A3 (en) * 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
DE60335915D1 (de) * 2002-12-20 2011-03-10 Amgen Inc Myostatin hemmende bindungsstoffe
AU2005289685B2 (en) 2004-09-24 2009-07-16 Amgen Inc. Modified Fc molecules
SI1772465T1 (sl) 2005-01-05 2009-06-30 F Star Biotech Forsch & Entw Sintetične imunoglobulinske domene z modificiranimi vezavnimi lastnostmi v regijah molekule, ki se razlikujejo od komplementarnost dolučujočih regij
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
EP1929073A4 (fr) * 2005-09-27 2010-03-10 Amunix Inc Produits pharmaceutiques proteiques et utilisations de ceux-ci
PL2500360T3 (pl) * 2005-10-31 2016-01-29 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworu
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
CA2632544C (fr) * 2005-12-06 2014-09-23 Amgen Inc. Utilisations d'antagonistes de la myostatine
JO3324B1 (ar) * 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
WO2007142954A2 (fr) * 2006-05-30 2007-12-13 Dow Global Technologies Inc. Procédé d'optimisation d'un codon
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
AT503889B1 (de) * 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AT503902B1 (de) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
US20090252703A1 (en) * 2006-10-19 2009-10-08 Gegg Jr Colin V Use of alcohol co-solvents to improve pegylation reaction yields
WO2008088422A2 (fr) * 2006-10-25 2008-07-24 Amgen Inc. Agents thérapeutiques à base de peptides toxiques
CA2669207A1 (fr) * 2006-11-10 2008-05-15 Covx Technologies Ireland Limited Composes anti-angiogeniques
AU2011202645B2 (en) * 2006-11-10 2012-07-12 Covx Technologies Ireland Limited Anti-angiogenic compounds
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
CA2687141C (fr) 2007-05-22 2014-04-01 Amgen Inc. Compositions et procedes pour produire des proteines de fusion bioactives
PL3241842T3 (pl) 2007-06-26 2024-06-10 F-Star Therapeutics Limited Prezentacja środków wiążących
EP2078091A4 (fr) * 2007-07-10 2010-09-01 Medimmune Llc Cristaux et structure du variant d'igg fc humain
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
NZ586701A (en) * 2008-01-03 2013-07-26 Scripps Research Inst Antibody targeting through a modular recognition domain (MRD) wherein the MRD targets angiopoietin-2 (ANG-2)
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8580927B2 (en) * 2008-01-31 2013-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered antibody constant domain molecules
EP2113255A1 (fr) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Immunoglobuline cytotoxique
WO2009142460A2 (fr) * 2008-05-23 2009-11-26 Samsung Electronics Co., Ltd. Corps synergique fusionné anticorps-peptide
US8637022B2 (en) 2008-06-30 2014-01-28 Esbatech, An Alcon Biomedical Research Unit Llc Functionalized polypeptides
US7926951B2 (en) * 2008-07-11 2011-04-19 Eastman Kodak Company Laser illuminated micro-mirror projector
JP5792621B2 (ja) 2008-09-26 2015-10-14 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
NZ627111A (en) 2008-11-26 2015-10-30 Amgen Inc Variants of activin iib receptor polypeptides and uses thereof
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2010091122A1 (fr) 2009-02-03 2010-08-12 Amunix, Inc. Polypeptides recombinants étendus et compositions les comprenant
WO2010096394A2 (fr) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Véhicules de médicaments à base de protéine marqués par aldéhyde et procédés d'utilisation
KR20110122846A (ko) * 2009-02-24 2011-11-11 알렉시온 파마슈티칼스, 인코포레이티드 치료용 ｔｐｏ/ｅｐｏ 모방 펩티드를 포함하는 항체
WO2010108153A2 (fr) 2009-03-20 2010-09-23 Amgen Inc. Immunoglobulines porteuses et utilisations de celles-ci
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
AU2010258898B8 (en) 2009-06-08 2015-02-05 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
EA020621B1 (ru) 2009-06-22 2014-12-30 Амген Инк. Рефолдинг белков с использованием химически контролируемого окислительно-восстановительного состояния
EP3660032A1 (fr) 2009-06-25 2020-06-03 Amgen, Inc Processus de purification de capture pour protéines exprimées dans un système non mammifère
US20120094874A1 (en) * 2009-07-09 2012-04-19 F-Star Biotechnologische Forschungs-Und Entwicklungsges. M.B.H Stabilized immunoglobulin constant domains
US20120263701A1 (en) * 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
AR080292A1 (es) * 2010-02-24 2012-03-28 Emisphere Tech Inc Metodo para normalizar en forma rapida los niveles de vitamina b12 en un paciente que tiene deficiencia de vitamina b12 y un nivel promedio de vitamina b12 por debajo de 350 pg/ml
MX347515B (es) 2010-04-01 2017-04-28 Oncomed Pharmaceuticals Inc * Agentes que se unen al receptor encrespado y usos de los mismos.
WO2011123830A2 (fr) 2010-04-02 2011-10-06 Amunix Operating Inc. Compositions d'alpha 1-antitrypsine, leurs procédés de préparation et d'utilisation
AU2011239470B2 (en) 2010-04-15 2015-09-10 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of Clostridium difficile-associated infection and disease
EP2579897A1 (fr) 2010-06-08 2013-04-17 Genentech, Inc. Anticorps et conjugués modifiés par la cystéine
EP2407487A1 (fr) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Anticorps modulaires multi-spécifiques
WO2012009705A1 (fr) 2010-07-15 2012-01-19 Zyngenia, Inc. Complexes liant ang-2 et leurs utilisations
EP2598530A2 (fr) 2010-07-29 2013-06-05 Xencor, Inc. Anticorps dont les points isoélectriques sont modifiés
CN103339145A (zh) 2010-09-22 2013-10-02 安姆根有限公司 运载体免疫球蛋白及其用途
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9783602B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
CA2824143C (fr) 2011-01-14 2018-12-18 Redwood Bioscience, Inc. Immunoglobulines polypeptidiques a marquage aldehydique et leur methode d'utilisation
US9340590B2 (en) 2011-03-16 2016-05-17 Amgen Inc. Potent and selective inhibitors of NaV1.3 and NaV1.7
PT2691417T (pt) 2011-03-29 2018-10-31 Roche Glycart Ag Variantes de fc de anticorpos
CN103702682A (zh) 2011-04-21 2014-04-02 科罗拉多州立大学董事会法人团体 治疗视神经脊髓炎的组合物和方法
ES2704038T3 (es) 2011-05-24 2019-03-13 Zyngenia Inc Complejos multiespecíficos multivalentes y monovalentes y sus usos
EP2546268A1 (fr) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Immunoglobuline s'internalisant
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
MX358358B (es) 2011-12-19 2018-08-15 Amgen Inc Polipeptidos de receptores de activina variantes y sus usos.
KR102208698B1 (ko) 2011-12-21 2021-01-29 암젠 인크 신생아 Fc 수용체에 대해 향상된 결합을 지니는 변이체 Fc-폴리펩타이드
CN104520321A (zh) 2012-01-09 2015-04-15 斯克利普斯研究所 超长互补决定区及其用途
EP2822577B1 (fr) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Protéines de facteur viii de recombinaison
LT2814840T (lt) 2012-02-15 2020-02-25 Bioverativ Therapeutics Inc. Faktoriaus viii kompozicijos ir jų gavimo ir naudojimo būdai
WO2013130683A2 (fr) 2012-02-27 2013-09-06 Amunix Operating Inc. Compositions de conjugués xten et leurs procédés de préparation
WO2013184514A1 (fr) * 2012-06-04 2013-12-12 Irm Llc Méthodes de marquage spécifiques à un site et molécules ainsi produites
US11142563B2 (en) * 2012-06-14 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified Fc region
ES2896493T3 (es) 2012-07-13 2022-02-24 Roche Glycart Ag Anticuerpos biespecíficos anti-VEGF/anti-ANG-2 y su uso en el tratamiento de enfermedades vasculares oculares
WO2014022102A1 (fr) 2012-08-01 2014-02-06 Amgen Inc. Procédés d'utilisation de composés anti-apoptotiques pour moduler une ou plusieurs propriétés d'une culture de cellules
WO2014030750A1 (fr) 2012-08-24 2014-02-27 中外製薬株式会社 ANTICORPS Fc SPÉCIFIQUE À FcyRII DE SOURIS
US9834597B2 (en) 2012-09-21 2017-12-05 The Regents Of The University Of California Modified FC polypeptides, FC conjugates, and methods of use thereof
CN104768579A (zh) 2012-10-23 2015-07-08 昂科梅德制药有限公司 使用Wnt途径结合剂来治疗神经内分泌肿瘤的方法
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
EP2943512A4 (fr) 2013-01-11 2016-06-01 California Inst Biomedical Res Anticorps bovins de fusion
WO2014109858A1 (fr) 2013-01-14 2014-07-17 Amgen Inc. Méthodes d'utilisation d'inhibiteurs de cycle cellulaire pour moduler une ou plusieurs propriétés d'une culture cellulaire
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
CN105051069B (zh) 2013-01-14 2019-12-10 Xencor股份有限公司 新型异二聚体蛋白
CA2897987A1 (fr) 2013-01-15 2014-07-24 Xencor, Inc. Elimination rapide de complexes antigeniques a l'aide de nouveaux anticorps
CN105431455A (zh) 2013-02-01 2016-03-23 圣塔玛丽亚生物疗法公司 抗激活素a化合物对受试者的施用
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
KR102447350B1 (ko) 2013-02-08 2022-09-23 노파르티스 아게 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
WO2014165277A2 (fr) 2013-03-12 2014-10-09 Amgen Inc. Inhibiteurs sélectifs et puissants de nav1.7
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (ar) * 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
EP2968463A4 (fr) * 2013-03-15 2016-11-23 Amgen Inc Antagonisme de la myostatine chez des sujets humains
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
AU2014232416B2 (en) 2013-03-15 2017-09-28 Xencor, Inc. Modulation of T Cells with Bispecific Antibodies and FC Fusions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
SG10201800800YA (en) 2013-05-06 2018-03-28 Scholar Rock Inc Compositions and methods for growth factor modulation
EP3033097B1 (fr) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Fusions de factor viii-xten et leurs utilisations.
WO2015035405A1 (fr) * 2013-09-09 2015-03-12 Pinta Biotherapeutics, Inc. Antagoniste de la myostatine pour le traitement de la dénutrition protéino-énergétique chez des patients atteints d'insuffisance rénale terminale
AU2014342232B2 (en) 2013-10-31 2017-12-21 Amgen Inc. Use of monensin to regulate glycosylation of recombinant proteins
TWI652279B (zh) 2013-11-11 2019-03-01 中外製藥股份有限公司 含改變的抗體可變區之抗原結合分子
US10106829B2 (en) 2014-01-29 2018-10-23 Amgen Inc. Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
KR102410393B1 (ko) 2014-01-29 2022-06-16 암젠 인크 재조합 단백질의 글리코실화를 조절하기 위한 n-글리코실화 경로 조절자의 과발현
EA201691925A1 (ru) 2014-03-28 2017-06-30 Ксенкор, Инк. Биспецифические антитела, которые связываются с cd38 и cd3
CA2943919A1 (fr) 2014-03-29 2015-10-08 Intas Pharmaceuticals Ltd. Composition pharmaceutique lyophilisee de proteine fusionnee avec un fc-peptide
WO2015187733A2 (fr) * 2014-06-02 2015-12-10 Pinta Biotherapeutics, Inc. Inhibiteurs de la myostatine pour le traitement du diabète
WO2015188135A1 (fr) * 2014-06-06 2015-12-10 The California Institute For Biomedical Research Protéines de fusion à anticorps à région constante et compositions les contenant
AR101844A1 (es) 2014-09-12 2017-01-18 Genentech Inc Anticuerpos y conjugados modificados genéticamente con cisteína
TW202313697A (zh) 2014-11-11 2023-04-01 日商中外製藥股份有限公司 包含經改變之抗體可變區之抗原結合分子的資料庫
BR112017011092A2 (pt) 2014-11-26 2017-12-26 Xencor Inc anticorpos heterodiméricos que ligam cd3 e antígenos de tumor
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
PE20171103A1 (es) 2014-11-26 2017-08-07 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y cd38
WO2016105450A2 (fr) 2014-12-22 2016-06-30 Xencor, Inc. Anticorps trispécifiques
WO2016141387A1 (fr) 2015-03-05 2016-09-09 Xencor, Inc. Modulation de lymphocytes t avec des anticorps bispécifiques et des hybrides fc
US11215616B2 (en) 2015-04-10 2022-01-04 National Institutes Of Health (Nih), (Dhhs), U.S. Government Methods of determining patient populations amenable to immunomodulatory treatment of cancer
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
EP4129327A1 (fr) 2015-08-28 2023-02-08 Amunix Pharmaceuticals, Inc. Ensemble polypeptides chimériques et leurs procédés de préparation et d'utilisation
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
US10227410B2 (en) 2015-12-07 2019-03-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
KR102501335B1 (ko) * 2015-12-18 2023-02-17 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CN109153728A (zh) 2016-03-21 2019-01-04 埃尔斯塔治疗公司 多特异性和多功能分子及其用途
KR20180135458A (ko) 2016-04-26 2018-12-20 알.피.쉐러 테크놀러지즈 엘엘씨 항체 컨쥬게이트 및 이의 제조 및 이용 방법
CA3024027A1 (fr) 2016-05-11 2017-11-16 Amgen Inc. Selection directe de cellules exprimant des teneurs elevees en proteines heteromeres a l'aide de vecteurs de complementation intragenique de glutamine synthetase
MX2018015592A (es) 2016-06-14 2019-04-24 Xencor Inc Anticuerpos inhibidores de puntos de control biespecificos.
JP7021127B2 (ja) 2016-06-28 2022-02-16 ゼンコア インコーポレイテッド ソマトスタチン受容体２に結合するヘテロ二量体抗体
CA3026050A1 (fr) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition pour la prophylaxie ou le traitement de maladies liees a il-8
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MX2019004327A (es) 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
US20200291089A1 (en) 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
WO2018222901A1 (fr) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Molécules multispécifiques se liant à une protéine de leucémie myéloproliférative (mpl) et leurs utilisations
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
GB201711208D0 (en) 2017-07-12 2017-08-23 Iontas Ltd Ion channel inhibitors
SG11202000801QA (en) * 2017-07-31 2020-02-27 Univ Tokyo Highly versatile method of presenting cyclic peptide on protein structure
WO2019035938A1 (fr) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Molécules multispécifiques se liant à bcma et leurs utilisations
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US11952422B2 (en) 2017-12-05 2024-04-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
JP2021506291A (ja) 2017-12-19 2021-02-22 ゼンコア インコーポレイテッド 改変されたｉｌ−２ ｆｃ融合タンパク質
WO2019178362A1 (fr) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Molécules multifonctionnelles se liant à calréticuline et utilisations associees
US20210009711A1 (en) 2018-03-14 2021-01-14 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
SG11202010163QA (en) 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
CA3097741A1 (fr) 2018-04-18 2019-10-24 Xencor, Inc. Proteines de fusion heterodimeres ciblant tim-3 contenant des proteines de fusion fc d'il-15/il-15ra et domaines de liaison a l'antigene de tim-3
MX2020012227A (es) * 2018-05-17 2021-04-13 Immunome Inc Epítopos marcadores del dominio ch3.
AU2019270184A1 (en) 2018-05-18 2020-11-26 Bioverativ Therapeutics Inc. Methods of treating hemophilia A
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
WO2020027224A1 (fr) * 2018-07-31 2020-02-06 国立大学法人東京大学 Procédé super-polyvalent permettant de conférer une nouvelle spécificité de liaison à un anticorps
EP3861016A2 (fr) 2018-10-03 2021-08-11 Xencor, Inc. Protéines de fusion fc hétérodimères d'il -12
AU2019410643A1 (en) 2018-12-21 2021-08-12 Jiangsu Hengrui Medicine Co., Ltd. Bispecific protein
JP2022522662A (ja) 2019-02-21 2022-04-20 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
AU2020226904A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
JP2022521937A (ja) 2019-02-21 2022-04-13 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
CA3130754A1 (fr) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Molecules multifonctionnelles se liant a des cellules cancereuses associees a des lymphocytes t et leurs utilisations
JP2022521750A (ja) 2019-02-21 2022-04-12 マレンゴ・セラピューティクス，インコーポレーテッド カルレティキュリンに結合する多機能性分子およびその使用
CN114173875A (zh) 2019-03-01 2022-03-11 Xencor股份有限公司 结合enpp3和cd3的异二聚抗体
CN113677702A (zh) 2019-04-01 2021-11-19 诺和诺德股份有限公司 针对利拉鲁肽的抗体及其用途
WO2021041715A2 (fr) * 2019-08-30 2021-03-04 University Of Kansas Compositions comprenant des mutations de fc d'igg et leurs utilisations
WO2021138407A2 (fr) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Molécules multifonctionnelles se liant à cd33 et utilisations associées
CA3170819A1 (fr) 2020-03-27 2021-09-30 Biotest Ag Proteine comprenant au moins un epitope d'activation des lymphocytes t regulateurs
AU2021250186A1 (en) 2020-03-31 2022-12-01 Chugai Seiyaku Kabushiki Kaisha DLL3-targeting multispecific antigen-binding molecules and uses thereof
WO2021217085A1 (fr) 2020-04-24 2021-10-28 Marengo Therapeutics, Inc. Molécules multifonctionnelles se liant à des cellules cancéreuses associées à des lymphocytes t et leurs utilisations
WO2021231976A1 (fr) 2020-05-14 2021-11-18 Xencor, Inc. Anticorps hétérodimères qui se lient à l'antigène membranaire spécifique de la prostate (psma) et cd3
CA3192204A1 (fr) 2020-08-19 2022-02-24 Xencor, Inc. Anticorps anti-cd28 et/ou compositions anti-b7h3
CA3190755A1 (fr) 2020-08-26 2022-03-03 Andreas Loew Molecules multifonctionnelles se liant a la calreticuline et utilisations associees
WO2022046922A2 (fr) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Molécules d'anticorps se liant à nkp30 et utilisations associees
JP2023540248A (ja) 2020-08-26 2023-09-22 マレンゴ・セラピューティクス，インコーポレーテッド Ｔｒｂｃ１またはｔｒｂｃ２を検出する方法
TW202233660A (zh) 2020-10-30 2022-09-01 美商安進公司 過表現胰島素樣生長因子受體突變體以調節ｉｇｆ補充
CA3212665A1 (fr) 2021-03-09 2022-09-15 Xencor, Inc. Anticorps heterodimeriques se liant a cd3 et a cldn6
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
JP2024515591A (ja) 2021-04-08 2024-04-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｔｃｒに結合する多機能性分子およびその使用
CN113402614A (zh) * 2021-04-22 2021-09-17 山东泉港药业有限公司 血小板生成素拟肽融合蛋白(fc-tmp)编码基因与应用
WO2022245259A1 (fr) * 2021-05-18 2022-11-24 Акционерное общество "ГЕНЕРИУМ" Procédé de purification industrielle de romiplostim
MX2023014680A (es) 2021-06-10 2024-01-12 Amgen Inc Variantes genomodificadas de la nrg-1 con una selectividad mejorada frente al erbb4 pero no frente al erbb3.
WO2023044774A1 (fr) * 2021-09-24 2023-03-30 Sichuan Clover Biopharmaceuticals, Inc. Protéines de fusion mimétiques de tpo et procédés d'utilisation de la soumission de listage de séquences dans un fichier de texte ascii
WO2023173084A1 (fr) 2022-03-11 2023-09-14 University Of Rochester Cyclopepticorps et leurs utilisations
WO2024133908A1 (fr) 2022-12-23 2024-06-27 Syna Therapeutics, S.L. Compositions pharmaceutiques stables comprenant du romiplostim

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US588763A (en) * 1897-08-24 Barrel-head
US580829A (en) * 1897-04-13 mcgrath
US3691016A (en) * 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
NL154598B (nl) * 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) * 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
CA1023287A (fr) * 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Procede de fixation d'une proteine sur un substrat
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3939350A (en) * 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US3941763A (en) * 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4087778A (en) * 1976-04-05 1978-05-02 Trw Inc. Termination for electrical resistor and method of making the same
US4195128A (en) * 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) * 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (fr) * 1977-02-17 1981-01-20 Hideo Hirohara Traduction non-disponible
US4229537A (en) * 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4277437A (en) * 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) * 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
DE3532226A1 (de) * 1985-08-13 1987-03-19 Sued Chemie Ag Katalysator zur verringerung des stickoxidgehalts von verbrennungsabgasen
US5985599A (en) * 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
NL8720442A (nl) * 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
ATE106249T1 (de) 1987-11-05 1994-06-15 Hybritech Inc Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik.
EP0325224B1 (fr) 1988-01-22 1996-07-31 ZymoGenetics, Inc. Procédé de préparation d'analogues de récepteurs sécrétés
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
JPH02503867A (ja) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ES2176174T3 (es) * 1988-12-22 2002-12-01 Genentech Inc Procedimiento de preparacion de polipeptidos solubles en agua.
US6406697B1 (en) * 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5216131A (en) * 1989-02-23 1993-06-01 Genentech, Inc. Lymphocyte homing receptors
US5098833A (en) * 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5627262A (en) * 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
EP1132471A3 (fr) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag Protéines liant le TNF
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE224911T1 (de) 1990-07-17 2002-10-15 Univ Oklahoma Gmp-140 ligand
WO1992016192A1 (fr) * 1991-03-15 1992-10-01 Amgen Inc. Administration pulmonaire d'un facteur de stimulation des populations de granulocytes
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
ES2252732T3 (es) * 1992-05-26 2006-05-16 Immunex Corporation Nueva citoquina que une cd30.
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
CA2142007C (fr) * 1992-08-11 2007-10-30 Robert Glen Urban Peptides immunomodulateurs
AU5098393A (en) 1992-08-14 1994-03-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant toxin with increased half-life
US5985450A (en) * 1993-09-22 1999-11-16 Shakespeare Striated monofilaments useful in the formation of papermaking belts
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5786331A (en) * 1994-02-02 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5608035A (en) * 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5880096A (en) * 1994-02-02 1999-03-09 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
AU714288B2 (en) 1994-06-28 1999-12-23 Merck & Co., Inc. Novel peptides
US5689452A (en) * 1994-10-31 1997-11-18 University Of New Mexico Method and apparatus for performing arithmetic in large galois field GF(2n)
AU693478B2 (en) * 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity
IL116026A (en) * 1994-11-22 2005-08-31 Rhone Poulenc Rorer Sa Peptides capable of linking to the sh3 domain of gap, nucleotide sequences encoding the same, their preparation and uses
US5888763A (en) 1994-12-30 1999-03-30 The Rockefeller University Peptides specific for the first Crk-SH3 domain
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5800096A (en) * 1995-04-27 1998-09-01 Barrow; Jeffrey Subsurface barrier wall and method of installation
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
JPH09151200A (ja) 1995-09-29 1997-06-10 Ajinomoto Co Inc ヒト胃癌に対する免疫応答を誘導できるペプチド及び該ペプチドを含むヒト胃癌治療、予防剤
US5838361A (en) * 1996-01-11 1998-11-17 Micron Technology, Inc. Laser marking techniques
US5714577A (en) * 1996-01-26 1998-02-03 University Of Pittsburgh Antimicrobial peptides
JP3636535B2 (ja) * 1996-03-14 2005-04-06 コニカミノルタビジネステクノロジーズ株式会社 現像方法
WO1997046668A1 (fr) 1996-06-07 1997-12-11 Takeda Chemical Industries, Ltd. Peptide, procede de production et mode d'utilisation correspondants
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
JP2002514201A (ja) * 1997-01-22 2002-05-14 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 凝固および腫瘍の処置のための組織因子の方法および組成物
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US5869151A (en) * 1997-06-26 1999-02-09 Boto (Licenses) Limited, An Isle Of Man Company Of 3/F Stand
US5932507A (en) * 1998-02-19 1999-08-03 Van Weeren; Remco Method for preventing low-temperature degradation of tetragonal zirconia containing materials
ES2218796T3 (es) 1998-05-21 2004-11-16 Tecnogen Scpa Uso de un compuesto peptidico para el tratamiento del lupus erimatoso sistemico.
US6117639A (en) 1998-08-31 2000-09-12 Vertex Pharmaceuticals Incorporated Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activity
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6133321A (en) * 1998-11-20 2000-10-17 Swift & Company Method for the reduction of stress in meat producing animals and meat produced from slaughtered animals treated thereby
IL147270A0 (en) 1999-07-02 2002-08-14 Genentech Inc Fusion peptides comprising a peptide ligand domain and a multimerization domain
WO2001004296A1 (fr) 1999-07-12 2001-01-18 Mcgill University Polypeptides rbp1 et leurs utilisations
WO2001083525A2 (fr) * 2000-05-03 2001-11-08 Amgen Inc. Peptides modifies utilises comme agents therapeutiques
CA2418835A1 (fr) * 2000-10-16 2002-04-25 Phylos, Inc. Echafaudages proteiniques internes pour analogues d'anticorps et autres proteines de liaison
GB0029407D0 (en) * 2000-12-01 2001-01-17 Affitech As Product
US6558702B2 (en) * 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
ES2387546T3 (es) * 2001-05-11 2012-09-25 Amgen Inc. Péptidos y moléculas relacionadas que se unen a TALL-1
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US20030215914A1 (en) * 2001-12-10 2003-11-20 Erwin Houtzager Structure for presenting desired peptide sequences
US6641144B2 (en) * 2001-12-28 2003-11-04 General Electric Company Supplemental seal for the chordal hinge seals in a gas turbine
EP1545608A4 (fr) 2002-06-28 2006-09-13 Centocor Inc Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
CA2490411A1 (fr) 2002-06-28 2004-01-08 Centocor, Inc. Corps mimetiques d'epo de mammifere a deletion ch1, compositions, methodes et utilisations associees
US6919426B2 (en) * 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
DE60335915D1 (de) * 2002-12-20 2011-03-10 Amgen Inc Myostatin hemmende bindungsstoffe
AU2005289685B2 (en) 2004-09-24 2009-07-16 Amgen Inc. Modified Fc molecules
SI1772465T1 (sl) 2005-01-05 2009-06-30 F Star Biotech Forsch & Entw Sintetične imunoglobulinske domene z modificiranimi vezavnimi lastnostmi v regijah molekule, ki se razlikujejo od komplementarnost dolučujočih regij

Also Published As

Publication number Publication date
ZA200702222B (en) 2009-04-29
US7750127B2 (en) 2010-07-06
US7750128B2 (en) 2010-07-06
WO2006036834A2 (fr) 2006-04-06
WO2006036834A3 (fr) 2006-06-29
US20060140934A1 (en) 2006-06-29
EP1797127B1 (fr) 2017-06-14
CN101103045A (zh) 2008-01-09
EA011879B1 (ru) 2009-06-30
EP1797127A2 (fr) 2007-06-20
US20090234104A1 (en) 2009-09-17
US7645861B2 (en) 2010-01-12
US20090286964A1 (en) 2009-11-19
US20090281286A1 (en) 2009-11-12
CN101103045B (zh) 2015-11-25
US7442778B2 (en) 2008-10-28
BRPI0516011A (pt) 2008-08-19
IL182139A0 (en) 2007-07-24
AU2005289685A1 (en) 2006-04-06
US20090012272A1 (en) 2009-01-08
US20090022744A1 (en) 2009-01-22
AU2005289685B2 (en) 2009-07-16
KR100920282B1 (ko) 2009-10-08
IL182139A (en) 2014-05-28
CA2580796C (fr) 2013-03-26
CA2580796A1 (fr) 2006-04-06
KR20070057975A (ko) 2007-06-07
JP5017116B2 (ja) 2012-09-05
US7655765B2 (en) 2010-02-02
US7655764B2 (en) 2010-02-02
EA200700623A1 (ru) 2007-12-28
US20090041768A1 (en) 2009-02-12
DK1797127T3 (en) 2017-10-02
ES2629397T3 (es) 2017-08-09
MX2007003320A (es) 2007-05-18
US7662931B2 (en) 2010-02-16
SI1797127T1 (sl) 2017-09-29
JP2008514201A (ja) 2008-05-08

Similar Documents

Publication Publication Date Title
MA28989B1 (fr) MOLECULES Fc MODIFIEES
DK1838736T3 (da) Cripto-bindende molekyler
DK1776383T3 (da) Bindingsmolekyler
DK1888645T3 (da) Anti-CD 16-bindende molekyler
DK2213683T3 (da) VARIANT-Fc-REGIONER
DE602006019691D1 (de) Polycarbonatdiol
DE602006021005D1 (de) Optisches mikrospektrometer
DE602005004378D1 (de) Rückbeleuchtungseinheit
DK1928882T3 (da) (s)-n-methylnaltrexon
ATE408603T1 (de) Pyrazolylcarboxanilide
CR9974A (es) Gavión
DE602006012066D1 (de) Daraus
ATE549324T1 (de) Tetrahydrobenzoxazine
DE602006010949D1 (de) Tragbare Leuchte
DE602006020744D1 (de) Fertigspritze
DK1877102T3 (da) Tab-molekyler
ATE485368T1 (de) Hiv - impfung
DE102005052834B8 (de) Punktschweißklebverbindung
AT501523A3 (de) Estrich
ATE454934T1 (de) Drehteller
DE602006018979D1 (de) Strahltrennendes optisches element
DE102006033170A8 (de) Einfassnähmaschine
DK1931573T3 (da) Lukke
DE112006001399A5 (de) Baueinheit
AT501968A3 (de) Mitführhilfe